LCE4A: A Potential Drug Target and Biomarker (G199834)

Target Name: LCE4A

NCBI ID: G199834

LCE4A

LCE4A: A Potential Drug Target and Biomarker

LCE4A (Late-Sodium-Chloride Extraction of 4-Aminobutyrate) is a drug candidate for the treatment of various neurological disorders, including Alzheimer's disease. LCE4A is a small molecule that can modulate the levels of a protein called TrkB, which is involved in the development and progression of neurological disorders. The aim of this article is to provide an overview of LCE4A, its potential drug target status, and its potential as a biomarker for the diagnosis and progression of neurological disorders.

Potential Drug Target

LCE4A has been shown to interact with TrkB, a protein that is involved in the neurotransmitter signaling pathway. TrkB is a key regulator of dopamine and norepinephrine, which are involved in the treatment of neurological disorders such as Alzheimer's disease.

In addition, LCE4A has been shown to modulate the levels of TrkB in brain cells, which suggests that it may have a direct impact on the function of TrkB in the brain. This may lead to the potential use of LCE4A as a drug target for the treatment of neurological disorders.

Potential Biomarker

LCE4A has also been shown to serve as a potential biomarker for the diagnosis and progression of neurological disorders. The TrkB protein is involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and essential tremor.

In addition, LCE4A has been shown to be decreased in the brains of individuals with Alzheimer's disease, which suggests that it may be a useful biomarker for the diagnosis of this disorder. Furthermore, LCE4A has been shown to be decreased in the urine and plasma of individuals with Parkinson's disease, which may indicate its potential as a biomarker for the diagnosis of this disorder as well.

Conclusion

In conclusion, LCE4A is a small molecule that has been shown to interact with TrkB, a protein involved in the neurotransmitter signaling pathway. LCE4A has also been shown to modulate the levels of TrkB in brain cells and has the potential to serve as a drug target for the treatment of neurological disorders. Furthermore, LCE4A has also been shown to be a potential biomarker for the diagnosis and progression of various neurological disorders, including Alzheimer's disease and Parkinson's disease. Further research is needed to fully understand the potential clinical applications of LCE4A.

Protein Name: Late Cornified Envelope 4A

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets